The development of a simple blood test for glioblastomas (GBMs),[1] a type of cancer affecting the brain or spine could make the diagnosis earlier and more effective. This finding is published in the journal The Royal Society Interface.
This finding was part of the wider University of Bristol-led CRUK project to develop an affordable, point-of-care blood test to diagnose brain cancer. This cross-disciplinary project combines biomarker discovery, the development of fluorescent nanoparticles, and new testing techniques with computational modeling.
How do you Detect Brain Cancer Early?
In this recent study mathematical models were developed and paired with experimental data. The researchers found that for the prospective GBM biomarker Glial fibrillary acidic protein (GFAP) lowering the current biomarker threshold could lead to earlier detection of GBMs.
‘The current use of biomarkers in the detection of brain cancer and how such biomarker-based strategies can be improved were assessed with a help of mathematical models.’
The team also used computational modeling to explore the impact of cancer characteristics and patient differences on detection and strategies for improvements.
These mathematical models could be used to examine and compare new biomarkers and tests for brain cancer as they emerge.
This new study provides the basis for further clinical data on the impact of lowering the current detection threshold for the known biomarker, GFAP, to allow earlier detection of GBMs using blood tests[2].
Advertisement
With further experimental data, it may also be possible to quantify cancer and patient heterogeneities and incorporate errors into our models and predictions for blood levels for different cancers.
Researchers have also demonstrated how our models can be combined with other diagnostics such as scans to enhance clinical insight to develop more personalized and effective treatments[3].
They are also hopeful this research will ultimately aid the development of a simple blood test for brain cancer, enabling earlier and more detailed diagnoses.
References :
1. https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme
Source: Medindia
Please use one of the following formats to cite this article in your essay, paper or report:
-
APA
Dr. Jayashree Gopinath. (2022, August 09). Simplifying Brain Cancer Diagnosis With New Blood Test. Medindia. Retrieved on Aug 09, 2022 from https://www.medindia.net/news/healthwatch/simplifying-brain-cancer-diagnosis-with-new-blood-test-208211-1.htm.
-
MLA
Dr. Jayashree Gopinath. ” Simplifying Brain Cancer Diagnosis With New Blood Test”. Medindia. Aug 09, 2022. <https://www.medindia.net/news/healthwatch/simplifying-brain-cancer-diagnosis-with-new-blood-test-208211-1.htm>.
-
Chicago
Dr. Jayashree Gopinath. ” Simplifying Brain Cancer Diagnosis With New Blood Test”. Medindia. https://www.medindia.net/news/healthwatch/simplifying-brain-cancer-diagnosis-with-new-blood-test-208211-1.htm. (accessed Aug 09, 2022).
-
Harvard
Dr. Jayashree Gopinath. 2021. Simplifying Brain Cancer Diagnosis With New Blood Test. Medindia, viewed Aug 09, 2022, https://www.medindia.net/news/healthwatch/simplifying-brain-cancer-diagnosis-with-new-blood-test-208211-1.htm.
Advertisement
